Reproductive Health-2017 Ferring Innovation Grant
Sponsor: Ferring Pharmaceuticals
Deadline:12th June 2017
Ferring is interested in funding exploratory, discovery and preclinical research into novel drug targets that are addressable with peptides and/or proteins.
The Ferring Innovation Grants are awarded annually in December and are not renewable. We will NOT fund clinical studies, proposals that require the collection of patient biopsies or studies to develop small molecules or intracellular targets.
Ferring is committed to building a portfolio of novel, innovative peptide-based drugs and biologicals to address the high unmet medical need for patients in our therapeutic areas of interest.
The areas include, but not limited to, Identification of targets with utility in the prevention and/or treatment of preterm labor or preeclampsia. New modalities for the treatment of endometriosis or menopausal symptoms. Improving fertility by targeting the molecular basis of embryo implantation, oocyte, embryo quality, FSH non-responders, anovulatory disorders, ovarian aging, polycystic ovarian syndrome or male factor infertility. Funding Grant amount can range from $50,000 to $100,000 USD. Investigators from around the world can apply. As the deadline is 12th June 2017, we are reaching out to see if your junior faculty would be interested.
The areas include, but not limited to, Identification of targets with utility in the prevention and/or treatment of preterm labor or preeclampsia. New modalities for the treatment of endometriosis or menopausal symptoms. Improving fertility by targeting the molecular basis of embryo implantation, oocyte, embryo quality, FSH non-responders, anovulatory disorders, ovarian aging, polycystic ovarian syndrome or male factor infertility. Funding Grant amount can range from $50,000 to $100,000 USD. Investigators from around the world can apply. As the deadline is 12th June 2017, we are reaching out to see if your junior faculty would be interested.
More information here: https://app.trialect.com/7169/display
No comments:
Post a Comment